Trial Watch

Figures & data

Table 1. Recent clinical trials testing purified TAAs or peptides thereof as therapeutic interventions in cancer patients.*

Indications	Phase	Status	Type	TAAs	Notes	Ref.
AML CML CMML MDS	I	Recruiting	Fusion proteins	NY-ESO-1	As Hiltonol^®-adjuvanted intervention, combined with decitabine	NCT01834248
	I/II	Recruiting	Fusion proteins	MAGEA10 WT1	As AS01B-adjuvanted intervention, following HSCT	NCT01819558
Breast carcinoma	I/II	Not yet recruiting	Peptides	ERBB2	Combined with trastuzumab ± PSK	NCT01922921
	II	Recruiting	Peptides	ERBB2	As standalone adjuvanted intervention	NCT01729884
CIN	I	Active, not recruiting	Fusion proteins	E7	As GPI-0100-adjuvanted intervention	NCT01880411
GBM	I	Not yet recruiting	Peptides	CMV-derived antigens	Combined with temozolomide	NCT01854099
	I/II	Recruiting	Peptides	Multiple	As Hiltonol^®-adjuvanted intervention, combined with temozolomide	NCT01920191
	II	Recruiting	HSP-TAA complexes	Multiple	Combined with bevacizumab	NCT01814813
Melanoma	I	Recruiting	Full length TAAs Peptides	NY-ESO-1	As Hiltonol^®- and Montanide ISA51-adjuvanted intervention, combined with ipilimumab	NCT01810016
	I	Recruiting	HSP-TAA complexes	gp100	As standalone adjuvanted intervention	NCT01744171
	I	Recruiting	Phosphopeptides	BCAR3 IRS2	As Hiltonol^®-, Montanide ISA51- and tetanus peptide-adjuvanted intervention	NCT01846143
	I/II	Recruiting	Peptides	MAGEA3.A1 NA17.A2	Combined with GM-CT-01	NCT01723813
	n.a.	Recruiting	Peptides	MART-1	As resiquimod- and Montanide ISA51-adjuvanted intervention, alone or combined with Gag267–274	NCT01748747
MPM	II	Recruiting	Peptides	WT1	As GM-CSF- and Montanide ISA51-adjuvanted intervention	NCT01890980
Multiple myeloma	I	Recruiting	Peptides	Multiple	As standalone adjuvanted intervention	NCT01718899
	n.a.	Recruiting	Peptides	WT1	As GM-CSF-adjuvanted intervention	NCT01827137
NSCLC	I	Withdrawn	Peptide-containing liposomes	MUC1	Combined with cyclophosphamide	NCT01731587
	I/II	Recruiting	Peptides	MUC1	As Hiltonol^®-adjuvanted intervention	NCT01720836
	I/II	Recruiting	Peptides	TERT	As GM-CSF-adjuvanted intervention	NCT01789099
Prostate cancer	I/II	Recruiting	Peptides	TERT	As GM-CSF-adjuvanted intervention	NCT01784913

Abbreviations: AML, acute myeloid leukemia; CIN, cervical intraepithelial neoplasia; CML, chronic myeloid leukemia; CMML, chronic myelomonocytic leukemia; CMV, cytomegalovirus; GBM, glioblastoma multiforme; GM-CSF, granulocyte-macrophage colony-stimulating factor; HSCT, hematopoietic stem cell transplantation; HSP, heat-shock protein; MDS, myelodysplastic syndrome; MPM, malignant pleural mesothelioma; MTC; medullary thyroid carcinoma; n.a., not available; NSCLC, non-small cell lung carcinoma; PSK, polysaccharide K; TAA, tumor-associated antigen. *started after September, 1st 2012 (source http://www.clinicaltrials.gov).